CD274 and prostate carcinoma: Consequently, mutations that inactivate SPOP impair ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and a reduction in tumor-infiltrating lymphocytes (TILs) in both mouse tumors and primary samples from prostate cancer patients.